

Chapter 41

REFERENCES

1. Lundy JS. Intravenous anesthesia; preliminary report of the use of two new thiobarbiturates. *Proc Staff Meet Mayo Clin.* 1935;10:536-543.
2. Goodman LS, Gilman AG. *The Pharmacological Basis of Therapeutics.* New York, NY: Macmillan; 1941.
3. Maker MT, Gregerson MS, Martin SM, et al. Free radical and drug oxidation products in an intensive care unit sedative: propofol with sulfite. *Crit Care Med.* 2003;31:787-792.
4. Sanna E, Garau F, Harris RA. Novel properties of homomeric beta 1 gamma-aminobutyric acid type A receptors: actions of the anesthetics propofol and pentobarbital. *Mol Pharmacol.* 1995;47:213-217.
5. Orser BA, Bertlik M, Wang LY, et al. Inhibition by propofol (2,6 di-isopropylphenol) of the N-methyl-D-aspartate subtype of glutamate receptor in cultured hippocampal neurons. *Br J Pharmacol.* 1995;116:1761-1768.
6. Cheng MA, Theard MA, Tempelhoff R. Intravenous agents and intraoperative neuroprotection. Beyond barbiturates. *Crit Care Clin.* 1997;13:185-199.
7. Samra SK, Sneyd JR, Ross DA, et al. Effects of propofol sedation on seizures and intracranially recorded epileptiform activity in patients with partial epilepsy. *Anesthesiology.* 1995;82:843-851.
8. Dwyer R, McCaughey W, Lavery J, et al. Comparison of propofol and methohexitone as anaesthetic agents for electroconvulsive therapy. *Anaesthesia.* 1988;43:459-462.
9. Veselis RA, Reinsel RA, Feshchenko VA, et al. The comparative amnesic effects of midazolam, propofol, thiopental, and fentanyl at equisedative concentrations. *Anesthesiology.* 1997;87:749-764.
10. Eames WO, Rooke GA, Wu RS, et al. Comparison of the effects of etomidate, propofol, and thiopental on respiratory resistance after tracheal intubation. *Anesthesiology.* 1996;84:1307-1311.
11. Grounds RM, Twigley AJ, Carli F. The haemodynamic effects of intravenous induction. Comparison of the effects of thio-pentone and propofol. *Anaesthesia.* 1985;40:735-740.
12. Sato M, Tanaka M, Umehara S, et al. Baroreflex control of heart rate during and after propofol infusion in humans. *Br J Anaesth.* 2005;94:577-581.
13. Kondo U, Kim SO, Nakayama M, Murray PA. Pulmonary vascular effects of propofol at baseline, during elevated vaso-motor tone, and in response to sympathetic alpha- and beta-adrenoceptor activation. *Anesthesiology.* 2001;94:815-823.
14. Sneyd JR, Carr A, Byrom WD, et al. A meta-analysis of nausea and vomiting following maintenance of anesthesia with propofol or inhalational agents. *Eur J Anesthesiol.* 1998;15:433-445.
15. Gan TJ, Glass PS, Howell ST, et al. Determination of plasma concentrations of propofol associated with 50% reduction in postoperative nausea. *Anesthesiology.* 1997;87:779-784.
16. DeBalli P. The use of propofol as an antiemetic. *Int Anesthesiol Clin.* 2003;41:67-77.
17. Appadu BL, Strange PG, Lambert DG. Does propofol interact with D2 dopamine receptors? *Anesth Analg.* 1994;79:1191-1192.
18. Saiah M, Borgeat A, Wilder-Smith OH, et al. Epidural-morphine-induced pruritus: propofol versus naloxone. *Anesth Analg.* 1994;78:1110-1113.
19. Yamakage M, Iwasaki S, Satoh JI, et al. Changes in concentrations of free propofol by modification of the solution. *Anesth Analg.* 2005;101:385-388.
20. Iwama H, Nakane M, Ohmori S, et al. Nafamostat mesilate, a kallikrein inhibitor, prevents pain on injection with propofol. *Br J Anaesth.* 1998;81:963-964.
21. Picard P, Tramèr MR. Prevention of pain on injection with propofol: a quantitative systematic review. *Anesth Analg.* 2000;90:963-969.
22. Hiraoka H, Yamamoto K, Miyoshi S, et al. Kidneys contribute to the extrahepatic clearance of propofol in humans, but not lungs and brain. *Br J Clin Pharmacol.* 2005;60:176-182.
23. Schnider TW, Minto CF, Gambus PL, et al. The influence of method of administration and covariates on the pharmacokinetics of propofol in adult volunteers. *Anesthesiology.* 1998;88:1170-1178.
24. Kanto J, Gepts F. Pharmacokinetic implications for the clinical use of propofol. *Clin Pharmacokin.* 1989;17:308-326.
25. Ickx B, Cockshott ID, Barvais L, et al. Propofol infusion for induction and maintenance of anaesthesia in patients with end-stage renal disease. *Br J Anaesth.* 1998;81:854-860.
26. Servin F, Cockshott ID, Farinotti R, et al. Pharmacokinetics of propofol infusions in patients with cirrhosis. *Br J Anaesth.* 1990;65:177-183.
27. Ouattara A, Boccarda G, Lemaire S, et al. Target-controlled infusion of propofol and remifentanyl in cardiac anaesthesia: influence of age on predicted effect-site concentrations. *Br J Anaesth.* 2003;90:617-622.

28. Shafer A, Doze VA, Shafer SL, et al. Pharmacokinetics and pharmacodynamics of propofol infusions during general anesthesia. *Anesthesiology*. 1988;69:348-356.
29. McDonald NJ, Mannion D, Lee P, et al. Mood elevation and outpatient anesthesia. A comparison between propofol and thiopentone. *Anaesthesia*. 1988;43(Suppl):68-69.
30. Hughes MA, Glass PS, Jacobs JR. Context-sensitive half-time in multicompartment pharmacokinetic models for intravenous anesthetic drugs. *Anesthesiology*. 1992;76:334-341.
31. Barr J, Egan TD, Sandoval NF, et al. Propofol dosing regimens for ICU sedation based upon an integrated pharmacokinetic-pharmacodynamic model. *Anesthesiology*. 2001;95:324-333.
32. Devlin JW, Lau AK, Tanios MA. Propofol-associated hypertriglyceridemia and pancreatitis in the intensive care unit: an analysis of frequency and risk factors. *Pharmacotherapy*. 2005;25:1348-1352.
33. Vasile B, Rasulo F, Candiani A, et al. The pathophysiology of propofol infusion syndrome: a simple name for a complex syndrome. *Intensive Care Med*. 2003;29:1417-1425.
34. Stanford University Department of Anesthesia. Stanford PK/PD Software Server. <http://anesthesia.stanford.edu/pkpd>. Accessed September 18, 2011.
35. Lusedra (fospropofol disodium) injection [package label]. Woodcliff Lake, NJ: Eisai; 2010.
36. Struys MM, Fechner J, Schüttler J, Schwilden H. Erroneously published fospropofol pharmacokinetic-pharmacodynamic data and retraction of the affected publications. *Anesthesiology*. 2010;112:1056-7.
37. Haws JL, Herman N, Clark Y, et al. The chemical stability and sterility of sodium thiopental after preparation. *Anesth Analg*. 1998;86:208-213.
38. Beeman CS, Dembo J, Bogardus A. Stability of reconstituted methohexital sodium. *J Oral Maxillofac Surg*. 1994;52:393-396.
39. Burt DR. Reducing GABA receptors. *Life Sci*. 2003;73:1741-1758.
40. Shapiro HM. Intracranial hypertension: therapeutic and anesthetic considerations. *Anesthesiology*. 1975;43:445-471.
41. Nehls DG, Todd MM, Spetzler RF, et al. A comparison of the cerebral protective effects of isoflurane and barbiturates during temporary focal ischemia in primates. *Anesthesiology*. 1987;66:453-464.
42. Brain Resuscitation Clinical Trial I Study Group. Randomized clinical study of thiopental loading in comatose survivors of cardiac arrest. *N Engl J Med*. 1986;314:397-403.
43. Hudson RJ, Stanski DR, Saidman LJ, et al. A model for studying depth of anesthesia and acute tolerance to thiopental. *Anesthesiology*. 1983;59:301-308.
44. Swanson RA, Seid LL. Barbiturates impair astrocyte glutamate uptake. *Glia*. 1998;24:365-371.
45. Mustafa S, Thulesius L, Thulesius O. The contractile response of thiopental in large and small ovine airways. *Acta Anesthesiol Scand*. 1994;38:499-504.
46. Chamberlain JH, Seed RG, Chung DC. Effect of thiopentone on myocardial function. *Br J Anaesth*. 1977;49:865-870.
47. Rich GF, Roos CM, Anderson SM, et al. Direct effects of intravenous anesthetics on pulmonary vascular resistance in the isolated rat lung. *Anesth Analg*. 1994;78:961-966.
48. Todd MM, Drummond JC, U HS. The hemodynamic consequence of high-dose thiopental anesthesia. *Anesth Analg*. 1985;64:681-687.
49. Lorenz W, Doenicke A, Meyer R, et al. Histamine release in man by propanidid and thiopentone: pharmacological effects and clinical consequences. *Br J Anaesth*. 1972;44:355-369.
50. Laxenaire MC. Epidemiology of anesthetic anaphylactoid reactions. Fourth multicenter survey (July 1994-December 1996). *Ann Fr Anesth Reanim*. 1999;18:796-809.
51. Desnick RJ. The porphyrias. In: Kasper DL, ed. *Harrison's Principles of Internal Medicine*. 16th ed. New York, NY: McGraw-Hill; 2004.
52. Archer DP, Ewen A, Roth SH, et al. Plasma, brain, and spinal cord concentrations of thiopental associated with hyperalgesia in the rat. *Anesthesiology*. 1994;80:168-176.
53. Russo H, Bressolle F. Pharmacodynamics and pharmacokinetics of thiopental. *Clin Pharmacokinet*. 1998;35:95-134.
54. Cordato DJ, Mather LE, Gross AS, et al. Pharmacokinetics of thiopental enantiomers during and following high-dose therapy. *Anesthesiology*. 1999;91:1693-1702.
55. Avram MJ, Krejcie TC, Henthorn TK. The relationship of age to the pharmacokinetics of early drug distribution: the concurrent disposition of thiopental and indocyanine green. *Anesthesiology*. 1990;72:403-411.
56. Hüter L, Schreiber T, Gugel M, Schwarzkopf K. Low-dose intravenous midazolam reduces etomidate-induced myoclonus: a prospective, randomized study in patients undergoing elective cardioversion. *Anesth Analg*. 2007;105:1298-1302.
57. Gooding JM, Weng JT, Smith RA. Cardiovascular and pulmonary responses following etomidate induction of anesthesia in patients with demonstrated cardiac disease. *Anesth Analg*. 1979;58:40-41.
58. Scorgie B. Etomidate infusion. Its use in anaesthesia for general surgery. *Anaesthesia*. 1983;38(Suppl):63-65.
59. Shapiro BM, Wendling WW, Ammaturo FJ, et al. Vascular effects of etomidate administered for electroencephalographic burst suppression in humans. *J Neurosurg Anesthesiol*. 1998;10:231-236.
60. Watt I, Ledingham IM. Mortality amongst multiple trauma patients admitted to an intensive therapy unit. *Anaesthesia*. 1984;39:973-981.
61. Allolio B, Dorr H, Stuttmann R, et al. Effect of a single bolus of etomidate upon eight major corticosteroid hormones and plasma ACTH. *Clin Endocrinol (Oxf)*. 1985;22:281-286.
62. Jackson WJ. Should we use etomidate as an induction agent for endotracheal intubation in patients with septic shock? A critical appraisal. *Chest*. 2005;127:1031-1038.
63. Mohammad Z, Afessa B, Finkelman JD. The incidence of relative adrenal insufficiency in patients with septic shock after the administration of etomidate. *Crit Care*. 2006;10:R105.
64. Cotton BA, Guillaumondegué OD, Fleming SB, et al. Increased risk of adrenal insufficiency following etomidate exposure in critically injured patients. *Arch Surg*. 2008;143:62.
65. Tekwani KL, Watts HF, Chan CW, et al. The effect of single-bolus etomidate on septic patient mortality: a retrospective review. *West J Emerg Med*. 2008;9:195.
66. Cuthbertson BH, Sprung CL, Annane D, et al. The effects of etomidate on adrenal responsiveness and mortality in patients with septic shock. *Intensive Care Med*. 2009;35:1868.
67. Ray DC, McKeown DW. Effect of induction agent on vasopressor and steroid use, and outcome in patients with septic shock. *Crit Care*. 2007;11:R56.

68. de Jong MF, Beishuizen A, Spijkstra JJ, et al. Predicting a low cortisol response to adrenocorticotrophic hormone in the critically ill: a retrospective cohort study. *Crit Care*. 2007;11:R61.
69. Riché FC, Boutron CM, Valleur P, et al. Adrenal response in patients with septic shock of abdominal origin: relationship to survival. *Intensive Care Med*. 2007;33:1761.
70. Tekwani KL, Watts HF, Rzechula KH, et al. A prospective observational study of the effect of etomidate on septic patient mortality and length of stay. *Acad Emerg Med*. 2009;16:11.
71. Jabre P, Combes X, Lapostolle F, et al. Etomidate versus ketamine for rapid sequence intubation in acutely ill patients: a multicentre randomised controlled trial. *Lancet*. 2009;374:293.
72. Crozier TA, Schlaeger M, Wuttke W, et al. TIVA with etomidate-fentanyl versus midazolam-fentanyl. The preoperative stress of coronary surgery overcomes the inhibition of cortisol synthesis caused by etomidate-fentanyl anesthesia. *Anaesthesist*. 1994;43:605-613.
73. Loftsson T, Gudmundsdóttir, Sigurjónsdóttir JF, et al. Cyclodextrin solubilization of benzodiazepines: formulation of midazolam nasal spray. *Int J Pharmaceut*. 2001;212:29-40.
74. Phillis JW, O'Regan MH. The role of adenosine in the central actions of the benzodiazepines. *Prog Neuropsychopharmacol Biol Psychiatry*. 1988;12:389-404.
75. MacDonald RL, McLean MJ. Anticonvulsant drugs: mechanism of action. *Adv Neurol*. 1986;44:713-736.
76. Hall PF. The role of endoepine in the regulation of steroid synthesis. *Mol Neurobiol*. 1995;10:1-17.
77. Dershwitz M, Rosow CE, Di Biase PM, et al. Comparison of the sedative effects of butorphanol and midazolam. *Anesthesiology*. 1991;74:717-724.
78. Reves JG, Fragan RJ, Vinik HR, et al. Midazolam: pharmacology and uses. *Anesthesiology*. 1985;62:310-324.
79. Buhner M, Maitre PO, Crevoisier C, et al. Electroencephalographic effects of benzodiazepines. II. Pharmacodynamic modeling of the electroencephalographic effects of midazolam and diazepam. *Clin Pharmacol Ther*. 1990;48:555-567.
80. Payne K, Mattheyse FJ, Liebenberg D, et al. The pharmacokinetics of midazolam in paediatric patients. *Eur J Clin Pharmacol*. 1989;37:267-272.
81. Marty J, Gauzit R, Lefevre P, et al. Effects of diazepam and midazolam on baroreflex control of heart rate and on sympathetic activity in humans. *Anesth Analg*. 1986;65:113-119.
82. Tomichek RC, Rosow CE, Philbin DM, et al. Diazepam-fentanyl interaction—hemodynamic and hormonal effects in coronary artery surgery. *Anesth Analg*. 1983;62:881-884.
83. Klotz U, Reimann I. Delayed clearance of diazepam due to cimetidine. *N Engl J Med*. 1980;302:1012-1014.
84. Hoffman EJ, Warren EW. Flumazenil: a benzodiazepine antagonist. *Clin Pharm*. 1993;12:641-656.
85. Gross JB, Weller RS, Conard P. Flumazenil antagonism of midazolam-induced ventilatory depression. *Anesthesiology*. 1991;75:179-185.
86. Zedkova L, Coupland NJ, Man GC, et al. Panic-related responses to pentagastrin, flumazenil, and thyrotropin-releasing hormone in healthy volunteers. *Depress Anxiety*. 2003;17:78-87.
87. Spivey WH. Flumazenil and seizures: analysis of 43 cases. *Clin Ther*. 1992;14:292-305.
88. Haverkos GP, DiSalvo RP, Imhoff TE. Fatal seizures after flumazenil administration in a patient with mixed overdose. *Ann Pharmacother*. 1994;28:1347-1349.
89. Himmelseher S, Pfenninger E. [The clinical use of S-(+)-ketamine—a determination of its place.] *Anesthesiol Intensivmed Notfallmed Schmerzther*. 1998;33:764-770.
90. Davies SN, Alford ST, Coan EJ, et al. Ketamine blocks an NMDA receptor-mediated component of synaptic transmission in rat hippocampus in a voltage-dependent manner. *Neurosci Lett*. 1988;92:213-217.
91. Schuttler J, Stanski DR, White PF, et al. Pharmacodynamic modeling of the EEG effects of ketamine and its enantiomers in man. *J Pharmacokinetic Biopharm*. 1987;15:241-253.
92. Schwartz MS, Virden S, Scott DF. Effects of ketamine on the electroencephalograph. *Anaesthesia*. 1974;29:135-140.
93. Harper MH, Hickey RF, Cromwell TH, et al. The magnitude and duration of respiratory depression produced by fentanyl and fentanyl plus droperidol in man. *J Pharmacol Exp Ther*. 1976;199:464-468.
94. Dershwitz M. Is droperidol safe? Probably.... *Semin Anesth Periop Med Pain*. 2004;23:291-301.
95. Nelson LE, Lu J, Guo T, et al. The α_2 -adrenoceptor agonist dexmedetomidine converges on an endogenous sleep-promoting pathway to exert its sedative effects. *Anesthesiology*. 2003;98:428-436.
96. Dawson C, Ma D, Chow A, et al. Dexmedetomidine enhances analgesic action of nitrous oxide. *Anesthesiology*. 2004;100:894-904.
97. Coursin DB, Coursin DB, Maccioli GA. Dexmedetomidine. *Curr Opin Crit Care*. 2001;7:221-226.
98. Belleville JP, Ward DS, Bloor BC, et al. Effects of intravenous dexmedetomidine in humans. I. Sedation, ventilation, and metabolic rate. *Anesthesiology*. 1992;77:1125-1133.
99. Gerlach AT, Dasta JF. Dexmedetomidine: an updated review. *Ann Pharmacother*. 2007;41:245-252.
100. Wijesundera DN, Naik JS, Beattie WS. Alpha-2 adrenergic agonists to prevent perioperative cardiovascular complications: a meta-analysis. *Am J Med*. 2003;114:742-752.
101. Cotten JF, Husain SS, Forman SA, et al. Methoxycarbonyl-etomidate: a novel rapidly metabolized and ultra-short-acting etomidate analogue that does not produce prolonged adrenocortical suppression. *Anesthesiology*. 2009;111:240-249.
102. Cotten JF, Forman SA, Laha JK, et al. Carboetomidate: a pyrrole analog of etomidate designed not to suppress adrenocortical function. *Anesthesiology*. 2010;112:637-644.
103. Upton RN, Martinez AM, Grant C. Comparison of the sedative properties of CNS 7056, midazolam, and propofol in sheep. *Br J Anaesth*. 2009;103:848-857.